Alternate-day add-on therapy with dapagliflozin in patients with type 2 diabetes mellitus: potential benefits and concerns. Issue 2 (1st February 2022)

• Record Type: Journal Article
• Authors: Singh, Harmanjit; Joshi, Dinesh; Narula, Seerat; Singla, Mandeep; Rohilla, Ravi; Singh, Jagjit
• Is Part Of: Expert review of clinical pharmacology. Volume 15:Issue 2(2022)
• Page Start: 197
• Page End: 203
• Publication Date: 2022-02-01
• Subjects: Adverse effects -- CHF -- compliance -- half-life -- pharmacokinetic -- SGLT2i; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2022.2053111
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction: Factors such as compliance, cost and safety play a major role in achieving the long-term goal in the management of type 2 diabetes mellitus (T2DM). Dapagliflozin carries a great potential of becoming an alternate-day therapy because of its favorable pharmacological properties. Areas covered: In this review, we have discussed and hypothesized the potential of dapagliflozin as an alternate-day add-on drug in T2DM patients. We have discussed the properties by virtue of which it carries a potential to become an alternate-day therapy. We have also explained the potential benefits and concerns of using this approach. Expert opinion: Alternate-day add-on therapy with dapagliflozin could be a promising approach in reducing the cost, improving the treatment satisfaction and reducing the adverse effects. However, this propsed indication demands an in-depth investigation among T2DM subjects who are not able to achieve glycemic control with standard monotherapy or combination therapy. Pilot studies or some small-scale investigator-initiated trials or academic clinical trials may be carried out to explore this concept. At the same time, large industry sponsored multicenter clinical trials including pharmacoeconomic analyses may be planned to have a more detailed investigation.